BG
MDGL icon

Bellevue Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bellevue Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51M Buy
4,675
+1,635
+54% +$838K 0.05% 92
2026
Q1 		$1.59M Buy
3,040
+156
+5% +$74.5K 0.04% 84
2025
Q4 		$1.68M Buy
2,884
+491
+21% +$251K 0.03% 101
2025
Q3 		$1.1M Buy
2,393
+1,293
+118% +$482K 0.02% 105
2025
Q2 		$333K Hold
1,100
– – 0.01% 114
2025
Q1 		$364K Hold
1,100
– – 0.01% 123
2024
Q4 		$339K Hold
1,100
– – 0.01% 132
2024
Q3 		$233K Hold
1,100
– – ﹤0.01% 142
2024
Q2 		$308K Buy
1,100
+40
+4% +$9.52K 0.01% 140
2024
Q1 		$283K Buy
+1,060
New +$250K ﹤0.01% 146

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group's MDGL Position: Q2 2026 in Review

Bellevue Group increased its Madrigal Pharmaceuticals (MDGL) stake by 54% in Q2 2026, buying an estimated $838K and bringing the position to 4,675 shares worth $2.51M. The position accounts for 0.05% of the portfolio, ranked #92.

Bellevue Group first reported a position in MDGL in Q1 2024 and has held it in 10 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Bellevue Group held 4,675 shares of Madrigal Pharmaceuticals worth $2.51M as of Q2 2026.
  • Bellevue Group bought 1,635 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $838K.
  • Madrigal Pharmaceuticals made up 0.05% of Bellevue Group's portfolio in Q2 2026, its #92 holding.
  • Bellevue Group first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.